|
IPC-PvPI adds 23 new AMCS under its ambit bringing total to 202
|
|
Suja Nair Shirodkar
June 27 , 2016
|
|
|
In a move to further bolster the Pharmcovigilence Programme of India
(PvPI), the Indian Pharmacopoeia Commission (IPC) recently added 23 new
adverse drug reaction monitoring centres (AMCs) under its ambit. With
this addition, IPC successfully established its foot prints across all
major locations in the country, for effective ADR monitoring bringing
the total number of AMCs under it to 202.
To ensure robust
functioning of the pharmacovigilence activities, IPC for the first time
identified some specialised hospitals as AMCs. These specialised
hospitals, now acting as AMCs will open up whole new database on
capturing of ADRs of the niche disease profiles they cater to, like
never before. Apart from collaborating with district level hospital’s
for ADRs reporting, new AMCS were strategically identified to ensure pan
India presence, based on the existence and non existence of the AMCs in
the states and union territories.
Dr V Kalaiselvan, principal
scientific officer, IPC informed that to ensure quality reporting of
ADRS and ensure patient safety, IPC, which acts as the national
coordinating centre (NCC) for the PvPI is currently focusing on capacity
building measures and skill development of these AMCS. He stressed that
since pharmacovigilance programme plays a vital role in ensuring the
drugs’ safety, it is important to focus on upgrading the current
reporting culture of ADRs under PvPI. This are being done through proper
induction, regular training and awareness programme, he added.
“We
can ensure success of this programme, only if we can effectively use it
to create awareness in ADRs reporting among health care professionals
under PvPI. Lack of knowledge of where, what and how ADRs should be
reported also affects reporting. So our key focus is on skill
development. Through this we aim to achieve maximum participation with
quality reporting to strengthen the ADR reporting across the country.
This is very important to ensure and improve patients’ safety and bring
in awareness of drug safety practices on science-based solutions for the
stakeholders,” Dr Kalaiselvan informed.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|